Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-450/r and ABT-267 in treatment-experienced Japanese adults with chronic hepatitis C virus infection
jRCT2080221883Phase 2
- Sponsor
- AbbVie Inc.
- Start
- Jul 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of paritaprevir, glecaprevir and ritonavir in chronic hepatitis C (CHC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of ABT-450/r with or without ABT-267, Antiviral activity of ABT-450/r with or without ABT-267 and 1 more.
02
Drugs
paritaprevirglecaprevirritonavir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080221883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221883.